Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Craig S. Owens who wrote (676)	9/14/1999 9:41:00 PM
From: Dr. John M. de Castro	Read Replies (1) of 1494

Yes, this is a significant milestone. It is no easy task to enroll significant numbers of patients in a clinical trial. Quintiles did an excellent job. We should see shortly just how good memantine is. The word is that Merz has their European Phase III data in hand. It should be published later this year. In the meantime, they have shared it with potential partners. The Pharmas were waiting to see these data before committing to a deal. IMHO, partnership discussions should be heating up significantly. This is an interesting and significant time for NTII. The waiting and speculating are nearly over. I'm psyched! Best regards John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next